OSAKA Titanium technologies : Notice of the 27th Annual General Meeting of Shareholders marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
With equipment that promises to produce 10 times more therapies, the deal with Cellares is hoped to make BSM's CAR-T ambitions more scalable and affordable
Bristol Myers Squibb (BMS) has entered into an agreement with Cellares to bolster the manufacturing of chimeric antigen receptor (CAR) T cell therapies.
Cellares, BMS announce $380M cell therapy manufacturing agreement njbiz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from njbiz.com Daily Mail and Mail on Sunday newspapers.
Bristol Myers Squibb will utilize Cellares’ proprietary Cell Shuttle, a next-generation end-to-end, fully automated cell therapy manufacturing platform, for the clinical and commercial-scale.